Glaukos
GKOS
Market cap $8.32B

150.88 USD

+7.14

4.97%

At close Dec 20, 4:00 PM EST

After hours

151.50

+0.62

0.41%

1 day

4.97%

5 days

9.04%

1 month

6.67%

3 months

18.08%

6 months

35.12%

Year to date

95.74%

1 year

89.55%

5 years

172.84%

10 years

383.28%

About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Employees: 907

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,809 funds

0

Analysts bullish %

of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 25

39% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 90

20% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]

11% more funds holding

Funds holding: 283 [Q2] → 313 (+30) [Q3]

7% more capital invested

Capital invested by funds: $6.63B [Q2] → $7.09B (+$454M) [Q3]

3.28% less ownership

Funds ownership: 111.26% [Q2] → 107.98% (-3.28%) [Q3]

30% less call options, than puts

Call options by funds: $19.5M | Put options by funds: $27.8M

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$120

20%

downside

Avg. target

$156

3%

upside

High target

$185

23%

upside

8 analyst ratings

7 positive

88%

0 neutral

0%

1 negative

13%

Truist Securities Richard Newitter 80% 1-year accuracy 40 / 50 met price target	23%upside $185	Buy Maintained	18 Dec 2024
Wells Fargo Larry Biegelsen 51% 1-year accuracy 24 / 47 met price target	1%upside $153	Overweight Maintained	11 Dec 2024
Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target	7%upside $162	Buy Upgraded	11 Dec 2024
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target	21%upside $182	Buy Initiated	6 Dec 2024
Stifel Thomas Stephan 31% 1-year accuracy 5 / 16 met price target	1%upside $153	Buy Maintained	2 Dec 2024

See Analyst Rankings

Financial journalist opinion

Based on 7 articles about GKOS published over the past 30 days

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Corporation (GKOS) is well-positioned to grow sales at a CAGR of ~20% to FY'27, potentially hitting $680mm in revenues and $90-$100mm post-tax earnings. The stock is currently valued at 21x sales, with high expectations for future growth, but a 27% margin of safety exists at current prices. GKOS's efficient asset base and strong cash conversion support sustainable growth, driven by iDose TR and iStent infinite uptake in domestic and international markets.

Glaukos: Still Bullish, But Embedded Expectations Are Now High

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for these events, where applicable, will be available in.

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Zacks Investment Research

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

Zacks Investment Research

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

Zacks Investment Research

5 Medical Device Stocks That Survived the 2024 Market Volatility

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

5 Medical Device Stocks That Survived the 2024 Market Volatility

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Zacks Investment Research

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

GKOS stock gains from strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.

Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?

Glaukos Announces Participation in Upcoming Investor Conferences

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY Stephens Annual Investment Conference on Wednesday, Novembe.

Glaukos Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

Glaukos Corp GKOS reported on Monday third-quarter sales of $96.7 million, up 24% year-over-year, beating the consensus of $91.49 million.

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds

See News Rankings

Charts implemented using Lightweight Charts™